Description
Key facts
Cell type:HEK-293,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9; X = 22 bp deletion, 19 bp deletion, 13 bp deletion, 1 bp insertion
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-IFNGR1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The IFNGR1 protein also known as Interferon Gamma Receptor 1 is an integral component of the cell surface receptor for interferon-gamma (IFN-γ). It possesses a mass of approximately 53 kDa. IFNGR1 is expressed in various cell types including immune cells such as T cells and macrophages and is also present in other cell lines like HEK 293. This receptor binds to its specific ligand IFN-γ initiating a series of intracellular events that are essential for immune response modulation.
Biological function summary
IFNGR1 functions as part of the interferon-gamma receptor complex working alongside the IFNGR2 subunit. This interaction with IFNGR2 is important for the receptor to properly transmit signals inside the cell. The binding of interferon-gamma to this receptor complex activates the JAK-STAT signaling pathway promoting the transcription of genes that enhance the antimicrobial activity of immune cells and regulate cellular immunity.
Pathways
The IFNGR1 protein plays an important role in the JAK-STAT signaling pathway which is critical for mediating responses to interferon-gamma. Upon activation by IFN-γ IFNGR1 recruits JAK kinases leading to the phosphorylation of STAT1 a significant transcription factor. STAT1 then dimerizes and translocates to the nucleus where it induces the expression of genes involved in immune defense and inflammation. This process is vital for the body's ability to handle infections and other immunological challenges.
IFNGR1 is associated with susceptibility to infections and certain immune-related disorders. Mutations or deficiencies in IFNGR1 can lead to Mendelian Susceptibility to Mycobacterial Disease (MSMD) where individuals show increased vulnerability to mycobacterial infections. Additionally improper signaling through IFNGR1 is linked to chronic granulomatous disease which can involve defective functioning of the NADPH oxidase complex. Understanding IFNGR1's function and interactions is important for exploring new therapeutic strategies for these disorders.
